TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31017382

Group type: EXPERIMENTAL
Intervention: Probiotic administration (specifically L. reuteri DSM 17938 strain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic administration during pregnancy and continued after birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine administration of probiotics to all infants
Number of subjects: 0
Study: 28727796

Group type: EXPERIMENTAL
Intervention: Health risk assessment (HRA) and monthly counselling sessions with a geriatrician over six months.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 200
Study: 25633634

Group type: EXPERIMENTAL
Intervention: Form‐Focused running using ChiRunning
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self‐directed training with educational materials
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional running
Number of subjects: 17
Study: 24246618

Group type: EXPERIMENTAL
Intervention: uBurn(©)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MerseyBurns(©)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Calculator
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 34
Study: 20664555

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 46

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 46
Study: 18641106

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 12 months
Number of subjects: 56
Study: 16202565

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 414
Study: 12957344

Group type: EXPERIMENTAL
Intervention: Nicotine patch (0, 21, 35 or 42 mg/day)
Number of subjects: 1039
Study: 10872897

Group type: EXPERIMENTAL
Intervention: Lean red meat
Number of subjects: 145
Study: 8941106

Group type: EXPERIMENTAL
Intervention: 6.25 mg BID carvedilol (low‐dose group)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 12.5 mg BID carvedilol (medium‐dose group)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 25 mg BID carvedilol (high‐dose group)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Combined carvedilol groups
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study: 1610414

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg b.i.d. for the first month, 240 mg b.i.d. for the second month)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d. for the first month, 50 mg b.i.d. for the second month)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of verapamil (240 mg b.i.d.) and captopril (50 mg b.i.d.)
Number of subjects: 30
Study: 3158903

Group type: EXPERIMENTAL
Intervention: Metronidazole suppositories (1 g, administered 8-hourly over 20 hours preceding surgery, then 12-hourly if applicable)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (500 mg infusion at the time of induction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both routes (suppositories and intravenous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31738653

Group type: EXPERIMENTAL
Intervention: Venetoclax (single low initiation dose)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Ibrutinib (8 cycles)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib and venetoclax
Number of subjects: 1
Study: 30466822

Group type: EXPERIMENTAL
Intervention: IV sodium bicarbonate
Number of subjects: 1161

Group type: COMPARATOR
Intervention: IV sodium chloride
Number of subjects: 1161

Group type: EXPERIMENTAL
Intervention: Oral acetylcysteine
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study: 26866428

Group type: EXPERIMENTAL
Intervention: Stopping TNFi treatment
Number of subjects: 817

Group type: COMPARATOR
Intervention: Continuation of TNFi treatment
Number of subjects: 817
Study: 24707184

Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI) using single-pill amlodipine/atorvastatin
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1417
Study: 23461076

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overall prognosis
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lung function values
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 77
Study: 20012012

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Beta cell function
Number of subjects: 602
Study: 18728908

Group type: EXPERIMENTAL
Intervention: Multifaceted evidence-based medicine intervention (didactic course + recurrent case-method learning sessions)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Peer-group sessions
Number of subjects: 14
Study: 16187865

Group type: EXPERIMENTAL
Intervention: Hot mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Musical mood induction (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit manipulation of moods (Study 3)
Number of subjects: 0
Study: 12067856

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate (TE) weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate (TE) weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate (TE) weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate (TE) weekly
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate (TE) weekly
Number of subjects: 61
Study: 10489659

Group type: EXPERIMENTAL
Intervention: 50 mg sertraline per day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8756812

Group type: EXPERIMENTAL
Intervention: Intermittent enteral feeding (IEF) 18 h/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous enteral feeding (CEF) 24 h/d
Number of subjects: 60
Study: 1764148

Group type: COMPARATOR
Intervention: Conventional hospital setting
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Birth room setting
Number of subjects: 114
Study: 6749959

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31445363

Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil (PSO) 3g/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28403351

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 40
Study: 26496252

Group type: EXPERIMENTAL
Intervention: DOF plus bevacizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: DOF
Number of subjects: 80
Study: 23584670

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21452953

Group type: EXPERIMENTAL
Intervention: Individual labeling of strollers (six different strollers labeled individually)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Category labeling of strollers (same six strollers labeled as 'stroller')
Number of subjects: 0
Study: 19633103

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (subcutaneous administration, dosed to achieve Hb concentration of 13.0 g/dL, not exceeding 14.5 g/dL)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Placebo (subcutaneous administration, sham adjustments of the dose)
Number of subjects: 2600
Study: 16449264

Group type: EXPERIMENTAL
Intervention: Fluticasone 250 microg with salmeterol 50 microg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fluticasone 250 microg without salmeterol
Number of subjects: 54
Study: 15566435

Group type: EXPERIMENTAL
Intervention: Patient-centered communication style
Number of subjects: 250

Group type: COMPARATOR
Intervention: Biomedical communication style
Number of subjects: 250
Study: 11774820

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) 1 mg/d for 20 days starting on 2 PBD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 9441152

Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secnidazole for 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secnidazole for 7 days
Number of subjects: 60
Study: 8381187

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) - 400 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 60 mg/m2 cisplatin, administered in four courses at 3-week intervals starting 30 days post-surgery.
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy).
Number of subjects: 269
Study: 3116821

Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NORPLANT‐2 implants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NORPLANT and NORPLANT‐2 implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin treatment
Number of subjects: 0
Study: 30925235

Group type: EXPERIMENTAL
Intervention: Brief lifestyle self-management intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 27792961

Group type: EXPERIMENTAL
Intervention: Cognitive-coping therapy (CCT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy plus CCT (pCCT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: OCD patients
Number of subjects: 31
Study: 26431718

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 80 ppm for 3 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inhaled nitrogen placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) for patients with hypoxemia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inhaled nitrogen placebo for patients with hypoxemia
Number of subjects: 100
Study: 23920009

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) during complex motor tasks
Number of subjects: 24
Study: 21395934

Group type: EXPERIMENTAL
Intervention: Baroque music
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control periods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Afternoon shift
Number of subjects: 0
Study: 18577269

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 17003642

Group type: EXPERIMENTAL
Intervention: Standard pancreaticoduodenectomy (PD)
Number of subjects: 117

Group type: COMPARATOR
Intervention: PD with extended lymphadenectomy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pylorus-preserving PD
Number of subjects: 117
Study: 14741658

Group type: EXPERIMENTAL
Intervention: Dichotic presentation of CV syllables
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binaural presentation of CV syllables
Number of subjects: 0
Study: 11473953

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study: 9608770

Group type: EXPERIMENTAL
Intervention: sucralfate + domperidone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ranitidine + domperidone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: omeprazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: optimal treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: proton pump inhibitors
Number of subjects: 40
Study: 7920492

Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: KPS <= 80
Number of subjects: 243
Study: 3191018

Group type: EXPERIMENTAL
Intervention: EMLA cream (eutectic mixture of lignocaine and prilocaine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20
Study: 31970125

Group type: EXPERIMENTAL
Intervention: Staples (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Subcuticular technique using monocryl 3-0 (group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Mattress suture nylon (2-0) (group C)
Number of subjects: 300
Study: 30839400

Group type: EXPERIMENTAL
Intervention: Paired nociceptive blink reflex (nBR) with inter-stimulus intervals (ISI) of 125 to 10000 milliseconds
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conditioned nBR/unconditioned nBR response ratio
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amplitude of conditioned nBR
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Average latency of unconditioned nR2
Number of subjects: 12
Study: 28427541

Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol 18/9.6 μg)
Number of subjects: 892
Study: 25935831

Group type: EXPERIMENTAL
Intervention: Tablet ranitidine, 150 mg; and tablet metoclopramide, 10 mg administered the night before and 2 hours before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No aspiration prophylaxis
Number of subjects: 60
Study: 24660591

Group type: EXPERIMENTAL
Intervention: Hypoglycemic anti-deafness capsules
Number of subjects: 296

Group type: COMPARATOR
Intervention: Glibenclamide and conventional drug treatment for deafness
Number of subjects: 296
Study: 21711508

Group type: EXPERIMENTAL
Intervention: ALA-rich oil
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 19
Study: 19882398

Group type: EXPERIMENTAL
Intervention: EB‐CME approved sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non EB‐CME approved sessions
Number of subjects: 0
Study: 17023848

Group type: EXPERIMENTAL
Intervention: 40 mg IV dexamethasone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 80 mg IV dexamethasone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 14511896

Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers in combination with diuretics, β-blockers, or calcium channel blockers
Number of subjects: 0
Study: 11115810

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day for 12 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9314453

Group type: EXPERIMENTAL
Intervention: Meningococcal septic shock treatment (specific intervention details not provided)
Number of subjects: 75
Study: 8392077

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Metoclopramide (7 mg/kg) plus dexamethasone (12 mg)
Number of subjects: 284
Study: 3326676

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: Codeine 60 mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 29724177

Group type: EXPERIMENTAL
Intervention: PREPARED
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PREPARED plus financial assistance
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 92
Study: 26677862

Group type: EXPERIMENTAL
Intervention: Ergocalciferol supplementation for 6 months
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Ergocalciferol supplementation
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 25681579

Group type: EXPERIMENTAL
Intervention: 2 hour computerized intervention for distress intolerance (DI) over two weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 53
Study: 23973155

Group type: EXPERIMENTAL
Intervention: Celecoxib (low and high dosages)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diclofenac (low and high dosages)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ibuprofen (low and high dosages)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Higher dosages of NSAIDs (Celecoxib, Diclofenac, Ibuprofen)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 90
Study: 20299286

Group type: EXPERIMENTAL
Intervention: Education, counseling and behavioral skill‐building program
Number of subjects: 106
Study: 18304961

Group type: EXPERIMENTAL
Intervention: Interim analysis of efficacy using time-related primary end points, >40% of which were overall survival.
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Early stopping of trials after interim analysis.
Number of subjects: 3300
Study: 15985582

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) at a target dose of 300 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at a target dose of 300 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-drug average
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 47
Study: 14664266

Group type: EXPERIMENTAL
Intervention: Stabident intraosseous injection
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: X-tip intraosseous injection
Number of subjects: 41
Study: 11712445

Group type: EXPERIMENTAL
Intervention: Children with atopic family history
Number of subjects: 52

Group type: COMPARATOR
Intervention: Children without atopic family history
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 8857478

Group type: EXPERIMENTAL
Intervention: Excimer laser-assisted balloon angioplasty
Number of subjects: 103

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 103
Study: 1512105

Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg orally, b.i.d.)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Cephalexin (500 mg orally, b.i.d.)
Number of subjects: 401
Study: 6361791

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg q.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 650 mg q.i.d.
Number of subjects: 0
Study: 31206155

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 280
Study: 29425923

Group type: EXPERIMENTAL
Intervention: Endoscopists trained in optical diagnosis with feedback
Number of subjects: 39

Group type: COMPARATOR
Intervention: Endoscopists trained in optical diagnosis without feedback
Number of subjects: 39
Study: 27543801

Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/Hypertension (HTN)
Number of subjects: 12808

Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/Normal blood pressure
Number of subjects: 12808

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance/Prehypertension
Number of subjects: 12808

Group type: EXPERIMENTAL
Intervention: Prediabetes (PreDM)/HTN
Number of subjects: 12808
Study: 25398129

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pre-dialysis education (MPE)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Non-MPE (control group)
Number of subjects: 425
Study: 21430358

Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training consisting of five tasks trained in 10 sessions.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 2
Study: 20589317

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg once daily
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Edoxaban 90 mg once daily
Number of subjects: 903

Group type: COMPARATOR
Intervention: Dalteparin (control) 2,500 IU initial, 5,000 IU subsequent doses once daily
Number of subjects: 903
Study: 17521052

Group type: EXPERIMENTAL
Intervention: Preventive measures including fluid volume loading, discontinuation of nephrotoxic medications 48 hours prior to the study, minimizing CM volume and frequency, avoiding high-osmolar contrast in renal impairment, considering iso-osmolar contrast.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iso-osmolar contrast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (AC)
Number of subjects: 0
Study: 15792898

Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 11905405

Group type: EXPERIMENTAL
Intervention: High-oxygen tension group (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low-oxygen tension group (n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 11057351

Group type: EXPERIMENTAL
Intervention: Emedastine ophthalmic solution 0.05% BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levocabastine ophthalmic suspension 0.05% BID
Number of subjects: 0
Study: 9376749

Group type: EXPERIMENTAL
Intervention: Gidazepam (20 mg test dose, 40 mg daily, 14-day course)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Phenazepam (0.5 mg and 1 mg test doses, daily dose 2 mg, 14-day course)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 8251874

Group type: EXPERIMENTAL
Intervention: Extended cognitive behavioral treatment (CB)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Relationship enhancement (RE)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Relationship and vocational enhancement (VE)
Number of subjects: 229
Study: 3899091

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29103126

Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement (TDR)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (control group)
Number of subjects: 82